z-logo
Premium
Characterization of a novel monoclonal antibody (V58A4) raised against a recombinant NH 2 ‐terminal heparin‐binding fragment of human endothelial cell thrombospondin
Author(s) -
Verônica Morandi,
L. Edelman,
Yves Legrand,
Chantal Legrand
Publication year - 1994
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(94)00460-9
Subject(s) - monoclonal antibody , recombinant dna , microbiology and biotechnology , chemistry , proteolysis , antibody , thrombospondin , thrombospondin 1 , thrombospondins , endothelial stem cell , polyclonal antibodies , heparin , biochemistry , biology , angiogenesis , in vitro , immunology , enzyme , cancer research , metalloproteinase , gene
We report herein the characterization of a mouse monoclonal antibody (Mab) raised against the recombinant NH 2 ‐terminal heparin‐binding domain (rHBD) of human endothelial cell thrombospondin (TSP). The antibody, a IgG1 (κ), hereafter referred to as V58A4, reacted with two rHBD, TSPN18 and TSPN28 (i.e. 18 kDa and 28 kDa, respectively) with an affinity constant of 1.33 × 10 −8 M. However, V58A4 failed to recognize native or deglycosylated forms of TSP purified from platelets or endothelial cells, as well as a 25–30 kDa HBD fragment produced by limited proteolysis of native TSP. In contrast, Mab V58A4 was shown to react with larger HBD fragments (50–60 kDa) that were present in platelet or endothelial cell extracts and could be retained on a heparin—Sepharose column at low salt concentrations. These fragments also reacted with MA‐II, a mouse Mab (IgG1), which recognizes both rHBD and HBD as well as intact TSP. Thus, V58A4 Mab appears to selectively recognize naturally occurring HBD fragments of TSP and may thus prove to be useful for detecting TSP proteolysis in situ under various physiopathological conditions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here